SEC Contract Filing

Filing Date: 2021-05-17

Document Content:
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>scyx-ex101_86.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
scyx-ex101_86.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_15"></a><a name="_cp_text_1_24"></a><a name="_cp_text_1_28"></a><a name="_cp_text_1_31"></a><a name="_cp_text_1_49"></a><a name="_cp_text_1_181"></a><a name="_cp_blt_2_200"></a><a name="_cp_text_1_209"></a><a name="_cp_blt_1_285"></a><a name="_cp_blt_2_284"></a><a name="_cp_text_1_455"></a><a name="_cp_text_1_465"></a><a name="_cp_blt_1_483"></a><a name="_cp_text_1_476"></a><a name="_cp_text_1_506"></a><a name="_cp_text_1_539"></a><a name="_cp_text_1_571"></a><a name="_dxtcompanion_actionscomplete"></a>[*] = Certain confidential information contained in this document, marked by brackets, is omitted because it is both (i) not material and (ii) is the type of information that&#160;SCYNEXIS,&#160;Inc. treats as private or confidential.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:18pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This <font style="font-weight:bold;font-variant: small-caps;">Exclusive License and Collaboration Agreement</font><font style="font-weight:bold;"> </font>(this &#8220;<font style="font-weight:bold;">Agreement</font>&#8221;) is made as of February 11, 2021 (the &#8220;<font style="font-weight:bold;">Effective Date</font>&#8221;), by and between <font style="font-weight:bold;font-variant: small-caps;">Scynexis, Inc</font><font style="font-variant: small-caps;">.,</font><font style="font-weight:bold;font-variant: small-caps;"> </font>a corporation organized and existing under the laws of the State of Delaware and having a place of business at 1 Evertrust Plaza, 13th Floor, Jersey City, NJ 07302, USA (&#8220;<font style="font-weight:bold;">Scynexis</font>&#8221;), and <font style="font-weight:bold;">Hansoh (Shanghai) Health Technology Co., Ltd.</font>, a corporation organized and existing under the laws of the People&#8217;s Republic of China having a place of business at Room 102, Block 1 No. 298 Xiangke Road, China (Shanghai) Pilot Free Trade Zone, China (&#8220;<font style="font-weight:bold;">Hansoh Healthtech</font>&#8221;) and<font style="font-weight:bold;"> Jiangsu Hansoh Pharmaceutical Group Company Limited</font>, a corporation organized and existing under the laws of the People&#8217;s Republic of China having a place of business at No. 9 Dongjin Road, Huaguoshan Avenue, Lianyungang, Jiangsu, China (&#8220;<font style="font-weight:bold;">Jiangsu Hansoh</font>&#8221; and together with Hansoh Healthtech, &#8220;<font style="font-weight:bold;">Hansoh</font>&#8221;).&nbsp;&nbsp;Scynexis and Hansoh are referred to in this Agreement individually as a &#8220;<font style="font-weight:bold;">Party</font>&#8221; and collectively as the &#8220;<font style="font-weight:bold;">Parties</font>.&#8221;&nbsp;&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-variant: small-caps;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;"><a name="_DV_M306"></a><a name="_DV_M310"></a>Recitals</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-variant: small-caps;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;">Whereas<font style="font-weight:normal;font-variant: normal;">, Scynexis is a biopharmaceutical company focused on the research and development of novel therapies for difficult-to-treat and often life-threatening infections, and is developing ibrexafungerp (formerly SCY-078), a novel glucan synthase inhibitor, for the treatment of fungal infections;&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-variant: small-caps;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;">Whereas<font style="font-weight:normal;font-variant: normal;">, Hansoh is a pharmaceutical company having experience in the development and commercialization of pharmaceutical products in the Greater China region; and </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-variant: small-caps;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;">Whereas<font style="font-weight:normal;font-variant: normal;">, Hansoh wishes to obtain an exclusive license from Scynexis to develop and commercialize, and a non-exclusive license to manufacture, ibrexafungerp and Product in the Greater China region, and Scynexis is willing to grant such a license to Hansoh, all in accordance with the terms and conditions set forth herein.&nbsp;&nbsp;</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-variant: small-caps;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;">Agreement</p>
<p style="text-align:justify;